AI Engines For more Details: Perplexity Kagi Labs You
Hormone Replacement Therapy: Dehydroisoandrosterone 3-acetate may be used as a precursor for the synthesis of androgens and estrogens in hormone replacement therapy. DHEA and its derivatives have been investigated for their potential benefits in improving hormone balance, enhancing mood, increasing energy levels, and promoting overall well-being, particularly in individuals with adrenal insufficiency or age-related hormonal decline.
Adrenal Insufficiency: In individuals with adrenal insufficiency, the adrenal glands do not produce enough cortisol and other steroid hormones, leading to symptoms such as fatigue, weakness, low energy levels, and mood disturbances. Dehydroisoandrosterone 3-acetate may be used as part of hormone replacement therapy to help restore hormonal balance and alleviate symptoms associated with adrenal insufficiency.
Aging and Age-Related Conditions: DHEA levels naturally decline with age, and supplementation with dehydroisoandrosterone 3-acetate has been proposed as a potential anti-aging intervention. Some studies suggest that DHEA supplementation may help improve muscle strength, bone density, cognitive function, and overall quality of life in older adults. However, more research is needed to fully understand the effects of DHEA supplementation on aging and age-related conditions.
Sex Hormone Imbalance: Dehydroisoandrosterone 3-acetate may be used to help restore hormonal balance in individuals with sex hormone imbalances, such as low testosterone or estrogen levels. It can serve as a precursor for the synthesis of androgens and estrogens in the body, helping to normalize hormone levels and alleviate symptoms associated with hormonal imbalances, such as low libido, erectile dysfunction, or menstrual irregularities.
Muscle Growth and Performance: Some athletes and bodybuilders may use dehydroisoandrosterone 3-acetate or DHEA supplements as a potential ergogenic aid to enhance muscle growth, strength, and athletic performance. However, the use of DHEA supplements for this purpose is controversial, and its efficacy and safety in improving athletic performance are not well-established. Moreover, the use of DHEA supplements in competitive sports may be prohibited by anti-doping regulations.
Metabolic and Cardiovascular Health: DHEA and its derivatives have been investigated for their potential effects on metabolic and cardiovascular health. Some studies suggest that DHEA supplementation may have favorable effects on insulin sensitivity, lipid profile, and cardiovascular risk factors. However, more research is needed to confirm these potential benefits and determine the optimal dosage and duration of DHEA supplementation for improving metabolic and cardiovascular health.
Side Effects and Risks: While dehydroisoandrosterone 3-acetate is generally considered safe when used appropriately and under medical supervision, it may cause side effects in some individuals, particularly at higher doses. Potential side effects may include acne, oily skin, hair loss, mood changes, insomnia, and changes in cholesterol levels. Long-term use of DHEA supplements may also have unknown risks, and individuals with certain medical conditions, such as hormone-sensitive cancers or prostate enlargement, should avoid DHEA supplementation.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.3 | -0.3 | |
ADHD | 4.7 | 4.7 | |
Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.3 | 0.67 |
Allergic Rhinitis (Hay Fever) | 1.1 | 1.4 | -0.27 |
Allergies | 4.8 | 2.1 | 1.29 |
Allergy to milk products | 1.6 | 1 | 0.6 |
Alopecia (Hair Loss) | 1.6 | 1.6 | |
Alzheimer's disease | 3.6 | 3.9 | -0.08 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.3 | 1.4 | 0.64 |
Ankylosing spondylitis | 4 | 1 | 3 |
Anorexia Nervosa | 0.3 | 1.5 | -4 |
Antiphospholipid syndrome (APS) | 2 | 2 | |
Asthma | 0.3 | 0.8 | -1.67 |
Atherosclerosis | 1.3 | 1.4 | -0.08 |
Atrial fibrillation | 2.8 | 1.7 | 0.65 |
Autism | 6.9 | 6.6 | 0.05 |
Barrett esophagus cancer | 0.5 | 0.2 | 1.5 |
benign prostatic hyperplasia | 0.4 | 0.4 | |
Bipolar Disorder | 1.5 | 1 | 0.5 |
Brain Trauma | 0.7 | 0.6 | 0.17 |
Carcinoma | 3.6 | 2.9 | 0.24 |
Celiac Disease | 2.8 | 3.5 | -0.25 |
Cerebral Palsy | 0.9 | 1.5 | -0.67 |
Chronic Fatigue Syndrome | 3.9 | 5.9 | -0.51 |
Chronic Kidney Disease | 1.8 | 0.6 | 2 |
Chronic Lyme | 0.6 | -0.6 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.8 | 0.2 | 8 |
Chronic Urticaria (Hives) | 1.7 | 1.2 | 0.42 |
Coagulation / Micro clot triggering bacteria | 1.7 | 1.3 | 0.31 |
Colorectal Cancer | 5.1 | 0.7 | 6.29 |
Constipation | 1.5 | 0.6 | 1.5 |
Coronary artery disease | 0.9 | 0.8 | 0.13 |
COVID-19 | 11.4 | 12.6 | -0.11 |
Crohn's Disease | 6.8 | 4.1 | 0.66 |
cystic fibrosis | 1.1 | 0.8 | 0.38 |
deep vein thrombosis | 1.1 | 0.9 | 0.22 |
Depression | 7.8 | 5.8 | 0.34 |
Dermatomyositis | 0.2 | 0.3 | -0.5 |
Eczema | 0.7 | 1.9 | -1.71 |
Endometriosis | 3.1 | 1.2 | 1.58 |
Eosinophilic Esophagitis | 0.2 | 0.3 | -0.5 |
Epilepsy | 3.1 | 2.5 | 0.24 |
Fibromyalgia | 2.7 | 1.8 | 0.5 |
Functional constipation / chronic idiopathic constipation | 5.9 | 3.5 | 0.69 |
gallstone disease (gsd) | 2.3 | 0.7 | 2.29 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2 | 1.1 | 0.82 |
Generalized anxiety disorder | 1.7 | 1.1 | 0.55 |
Glioblastoma | 0.2 | -0.2 | |
Graves' disease | 1.4 | 1.3 | 0.08 |
Halitosis | 0.9 | 0.2 | 3.5 |
Hashimoto's thyroiditis | 2.4 | 0.6 | 3 |
Hidradenitis Suppurativa | 0.4 | 0.3 | 0.33 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 2.8 | 0.8 | 2.5 |
hypercholesterolemia (High Cholesterol) | 0.3 | 0.2 | 0.5 |
hyperglycemia | 0.4 | 1.6 | -3 |
Hyperlipidemia (High Blood Fats) | 0.8 | 0.4 | 1 |
hypersomnia | 0.4 | -0.4 | |
hypertension (High Blood Pressure | 2.5 | 3.8 | -0.52 |
Hypothyroidism | 0.7 | -0.7 | |
Hypoxia | 0.8 | 0.8 | |
IgA nephropathy (IgAN) | 2.9 | -2.9 | |
Inflammatory Bowel Disease | 4.4 | 6.2 | -0.41 |
Insomnia | 1 | 0.6 | 0.67 |
Intelligence | 0.8 | 0.4 | 1 |
Intracranial aneurysms | 1.6 | 0.4 | 3 |
Irritable Bowel Syndrome | 4.3 | 4.2 | 0.02 |
Liver Cirrhosis | 4 | 2.3 | 0.74 |
Long COVID | 6.4 | 7.5 | -0.17 |
Low bone mineral density | 0.2 | -0.2 | |
Lung Cancer | 1.2 | 1.4 | -0.17 |
ME/CFS with IBS | 0.6 | 2.1 | -2.5 |
ME/CFS without IBS | 0.4 | 2.2 | -4.5 |
Menopause | 2 | 2 | |
Metabolic Syndrome | 7.1 | 7.4 | -0.04 |
Mood Disorders | 9.5 | 5.8 | 0.64 |
multiple chemical sensitivity [MCS] | 1.4 | 0.4 | 2.5 |
Multiple Sclerosis | 4 | 3.2 | 0.25 |
Multiple system atrophy (MSA) | 0.9 | 1.2 | -0.33 |
Neuropathy (all types) | 0.7 | 0.4 | 0.75 |
neuropsychiatric disorders (PANDAS, PANS) | 1.1 | 1.1 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.1 | 3.9 | -0.86 |
NonCeliac Gluten Sensitivity | 0.3 | -0.3 | |
Obesity | 7.5 | 4.1 | 0.83 |
obsessive-compulsive disorder | 8 | 3 | 1.67 |
Osteoarthritis | 1.6 | 0.5 | 2.2 |
Osteoporosis | 1.6 | 0.9 | 0.78 |
pancreatic cancer | 0.6 | 0.6 | |
Parkinson's Disease | 2.2 | 3.4 | -0.55 |
Polycystic ovary syndrome | 2.7 | 1.8 | 0.5 |
Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
Premenstrual dysphoric disorder | 1.1 | 0.3 | 2.67 |
primary biliary cholangitis | 0.3 | 1.2 | -3 |
Psoriasis | 4.8 | 1.9 | 1.53 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5 | 3.2 | 0.56 |
Rosacea | 1.5 | 0.2 | 6.5 |
Schizophrenia | 5 | 1.4 | 2.57 |
scoliosis | 0.5 | -0.5 | |
Sjögren syndrome | 3.1 | 3.2 | -0.03 |
Sleep Apnea | 1.4 | 1 | 0.4 |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.2 | 0.5 | 1.4 |
Stress / posttraumatic stress disorder | 2.6 | 1.4 | 0.86 |
Systemic Lupus Erythematosus | 3.3 | 1.7 | 0.94 |
Tic Disorder | 1.6 | 1.4 | 0.14 |
Tourette syndrome | 0.1 | 0.4 | -3 |
Type 1 Diabetes | 4.3 | 1.8 | 1.39 |
Type 2 Diabetes | 7.9 | 6.9 | 0.14 |
Ulcerative colitis | 2.8 | 4.6 | -0.64 |
Unhealthy Ageing | 4.7 | 0.9 | 4.22 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.